Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Details including numerical values for the quantitative analysis obtained from the Progenesis LC-MS software are shown in Additional file 1.Protein expression differences among experimental groups at different time points (30 min, 1 h, 4 h and 48 h)LPS_CholineP02081; Hemoglobin fetal subunit beta/1.52Q9QAQ7; Non structural protein of 4 9 kDa/3.42P02676; Fibrinogen beta chain/3.83 A2I7N1; Serpin A3 5/1.44 Q3ZC07*; Actin alpha cardiac muscle 1/15.21 Q32L76; Serum amyloid A 4 protein/1.70 A2I7N3; Serpin A3 7/1.44 Q3ZC07*; Actin alpha cardiac muscle 1/187.33 P0CH28*; Polyubiquitin C/1.59 P12799; Fibrinogen gamma B chain/8.44 Q2M2T2; U-p-C19orf71-h/2.17 P02676; Fibrinogen beta chain/64.53 A2I7N1; Serpin A3 5/1.44Q9TTK6; Membrane primary amine oxidase/InfinityP01966; Hemoglobin subunit alpha/1.50P19034; Apolipoprotein C II/2.82 Q9MYP6; beta hydroxysteroid dehydrogenase 14/26.44 Q1JQ97; Bardet Biedl syndrome 4 protein homolog/2.30 Q9TTK6; Membrane primary amine oxidase/11.79 P81644; Apolipoprotein A II/1.45 P19035; Apolipoprotein C III/2.34 Q32L76; Serum amyloid A 4 protein/2.20 Q5E9E3; Complement C1q subcomponent subunit A/3.01 P34955; Alpha 1 antiproteinase/1.60 P28800; Alpha 2 antiplasmin/1.43 P80012; von Willebrand factor Fragment/2.98 Q9TTE1; Serpin A3 1/2.09Q80E01; Glutaredoxin 1/2.21Q3SZJ0; Argininosuccinate lyase/1.81Q17QL1; Glucosamine 6 phosphate isomerase 2/2.96Q3T0Z5; Leukocyte receptor cluster m-1-h/2.22 Q9TTE1; Serpin A3 1/1.74 Q9TTK6; Membrane primary amine oxidase/64.58 A2I7N0; Serpin A3 4/1.47 P41361; Antithrombin III/2.67 P00735; Prothrombin/2.287 P12799; Fibrinogen gamma B chain/5.92 LPS P17697; Clusterin/1.43 Q0V898; Negative elongation factor E/1.68 Q9TTK6; Membrane primary amine oxidase/7.17 A6QPQ2; Serpin A3 8/1.67 O46406; Primary amine oxidase lung isozyme/3.74 P01044; Kininogen 1/2.13 A7E3W2; Galectin 3 binding protein/13.09 P41356; Fusion glycoprotein F0/1.82 O62830-2; Isoform Beta 2 of Protein phosphatase 1B/6.78 Q3T132; Ragulator complex protein LAMTOR2/189.56 Q3SZJ0; Argininosuccinate lyase/9.22 Q9QAQ7; Bovine coronavirus strain OK 0514 GN 4a/4.93 Q0V898; Negative elongation factor E/10.86 Q28901;6-p-2-k-f-2-6-b-f/Infinity A2I7N2; Serpin A3 6/1.64 P81644; Apolipoprotein A II/1.62 P19035; Apolipoprotein C III/2.80 Q5E9E3; Complement C1q subcomponent subunit A/2.66 Q28901; 6-p-2-k-f-2-6-b-f/infinity P01966; Hemoglobin subunit alpha/1.81 P02081; Hemoglobin fetal subunit beta/1.55 P80109; P-g-s-p-d/1.50 Q5E9F5; Transgelin 2/2.90 P22226; Cathelicidin 1/13.17 Q7SIH1; Alpha 2 macroglobulin/1.41 A2I7M9; Serpin A3 2/9.68 P00924; ENO1 YEAST Enolase 1/1.46 Q3MHN5; Vitamin D binding protein/1.67 Q3ZC07*; Actin alpha cardiac muscle 1/25.52 P80109; Phosphatidylinositol glycan specific phospholipase D/3.11 O02659; Mannose binding protein C/5.76 P0CH28*; Polyubiquitin C/4.09 A8YXX7; Trefoil factor 3/4.93 Q2TBS3; Uncharacterized protein C20orf79 homolog/4.76 Q96629; Adenain/2.23 P19034; Apolipoprotein C II/4.21 Q1JP73; UPF0553 protein C9orf64 homolog/12.57 Q9TTK6-2; Isoform 2 of Membrane primary amine oxidase/2.30Q1JP73; UPF0553 protein C9orf64 homolog/1.95Q56K14; 60S acidic ribosomal protein P1/Infinity Q3SZV7; Hemopexin/2.10 Q1JQ97; Bardet Biedl syndrome 4 protein homolog/1.48 Q56K14;60S acidic ribosomal protein P1/Infinity Q96629; Adenain/1.74 Q2KIT0; Protein HP 20 homolog/1.93 Q5E9F5; Transgelin 2/Infinity P62803; Histone H4/11.67 CholineO46406; Primary amine oxidase lung isozyme/1.74Q28901; 6-p-2-k-f-2-6-b-f/Infinity Q2M2T2; Uncharacterized protein C19orf71/1.78 A2I7N3; Serpin A3 7/1.56 Q17QL1; Glucosamine 6 phosphate isomerase 2/1.48 A5PJC4; Ubiquitin ISG15 c. e.

Source: Serum proteins. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Changes in serum proteins after endotoxin administration in healthy and choline-treated calves

Study design awaiting verification · BMC Veterinary Research · 2016

Original publication title

Changes in serum proteins after endotoxin administration in healthy and choline-treated calves

Z. Yilmaz; O. Eralp Inan; M. Kocaturk; A. T. Baykal; O. Hacariz; I. Hatipoglu; A. Tvarijonaviciute; M. Cansev; J. Ceron; I. H. Ulus

© The Author(s). 2016

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

LPS administration produces changes in serum proteins associated with lipid metabolism, immune and inflammatory response, protein binding/transport, cell adhesion, venous thrombosis, cardiac contractility and blood coagulation. The administration of choline is associated with changes in proteins which can be related with its beneficial effect in this clinical situation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

This study aimed to investigate the possible serum protein changes after endotoxin administration in healthy and choline-treated calves using proteomics. These results are expected to contribute to the understanding of the pathophysiological mechanisms of endotoxemia and the beneficial effect of choline administration in this clinical situation.

Source: Background

Abstract: What methods does the paper describe?

Healthy-calves (n = 20) were divided into 4 groups: Control, Choline treated (C), Lipopolysaccharide administered (LPS), and LPS + C. Control calves received 0.9 % NaCl injection. Calves in C and LPS + C groups received choline chloride (1 mg/kg/iv). Endotoxin (LPS) was injected (2 μg/kg/iv) to the calves in LPS and LPS + C groups. Serum samples were collected before and after the treatments. Differentially expressed proteins (> 1.5 fold-change relative to controls) were identified by LC-MS/MS.

Source: Methods

Abstract: Electronic supplementary material

The online version of this article (doi:10.1186/s12917-016-0837-y) contains supplementary material, which is available to authorized users.

Source: Electronic supplementary material

Abstract: Results

After LPS administration, 14 proteins increased, and 13 proteins decreased within 48 h as compared to controls. In the LPS group, there were significant increases in serum levels of ragulator complex protein (189-fold) and galectin-3-binding protein (10-fold), but transcription factor MafF and corticosteroid binding globulin were down regulated (≥ 5 fold). As compared with the LPS group, in LPS + C group, fibrinogen gamma-B-chain and antithrombin were up-regulated, while hemopexin and histone H4 were down-regulated. Choline treatment attenuated actin alpha cardiac muscle-1 overexpression after LPS.

Source: Results

Abstract: Conclusions

LPS administration produces changes in serum proteins associated with lipid metabolism, immune and inflammatory response, protein binding/transport, cell adhesion, venous thrombosis, cardiac contractility and blood coagulation. The administration of choline is associated with changes in proteins which can be related with its beneficial effect in this clinical situation.

Source: Conclusions
Authors’ abstract

Background

This study aimed to investigate the possible serum protein changes after endotoxin administration in healthy and choline-treated calves using proteomics. These results are expected to contribute to the understanding of the pathophysiological mechanisms of endotoxemia and the beneficial effect of choline administration in this clinical situation.

Methods

Healthy-calves (n = 20) were divided into 4 groups: Control, Choline treated (C), Lipopolysaccharide administered (LPS), and LPS + C. Control calves received 0.9 % NaCl injection. Calves in C and LPS + C groups received choline chloride (1 mg/kg/iv). Endotoxin (LPS) was injected (2 μg/kg/iv) to the calves in LPS and LPS + C groups. Serum samples were collected before and after the treatments. Differentially expressed proteins (> 1.5 fold-change relative to controls) were identified by LC-MS/MS.

Results

After LPS administration, 14 proteins increased, and 13 proteins decreased within 48 h as compared to controls. In the LPS group, there were significant increases in serum levels of ragulator complex protein (189-fold) and galectin-3-binding protein (10-fold), but transcription factor MafF and corticosteroid binding globulin were down regulated (≥ 5 fold). As compared with the LPS group, in LPS + C group, fibrinogen gamma-B-chain and antithrombin were up-regulated, while hemopexin and histone H4 were down-regulated. Choline treatment attenuated actin alpha cardiac muscle-1 overexpression after LPS.

Conclusions

LPS administration produces changes in serum proteins associated with lipid metabolism, immune and inflammatory response, protein binding/transport, cell adhesion, venous thrombosis, cardiac contractility and blood coagulation. The administration of choline is associated with changes in proteins which can be related with its beneficial effect in this clinical situation.

Electronic supplementary material

The online version of this article (doi:10.1186/s12917-016-0837-y) contains supplementary material, which is available to authorized users.

Publication and source details

Original title: Changes in serum proteins after endotoxin administration in healthy and choline-treated calves

Z. Yilmaz; O. Eralp Inan; M. Kocaturk; A. T. Baykal; O. Hacariz; I. Hatipoglu; A. Tvarijonaviciute; M. Cansev; J. Ceron; I. H. Ulus

BMC Veterinary Research · 2016

© The Author(s). 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.TÜBTAK111O026

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:58:48.325732+00:00

DOI: 10.1186/s12917-016-0837-y · PMC5028968